COVID‐19 in lung transplant recipients

Myers, C.N.; Scott, J.; Criner, Gerard J.; Cordova, Francis; Mamary, A.J.; Marchetti, Nathaniel; Shenoy, Kartik; Galli, J.; Mulhall, P.; Brown, James R.; Shigemura, Norihisa; Sehgal, Sameep

doi:10.1111/tid.13364

Cited by 43 publications

(62 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The hospital outcomes in the largest case series from Spain were poor, with more than 80% of the patients developing respiratory failure and nearly 40% succumbing to the infection. Similarly, in New York, 34% of the LT patients with COVID-19 succumbed within 2 weeks of illness [18], while the mortality rate was 25% in a series from Philadelphia [17]. Conversely, the outcomes from the Belgian series [20] appeared to be better, although it included only 10 patients.…”

Section: Discussionmentioning

confidence: 98%

“…The earlier series describing COVID-19 in LT patients from the United States [ 6 , 17 , 18 ] as well as from Spain [19] , Belgium [20] and France [21] reported markedly variable patient outcomes despite being from the same time period. The hospital outcomes in the largest case series from Spain were poor, with more than 80% of the patients developing respiratory failure and nearly 40% succumbing to the infection.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical characteristics, management practices, and outcomes among lung transplant patients with COVID-19

Mohanka

Mahan

Joerns

et al. 2021

The Journal of Heart and Lung Transplantation

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

Section: Discussionmentioning

confidence: 98%

Section: Discussionmentioning

confidence: 99%

Clinical characteristics, management practices, and outcomes among lung transplant patients with COVID-19

Mohanka

Mahan

Joerns

et al. 2021

The Journal of Heart and Lung Transplantation

View full text Add to dashboard Cite

show abstract

“…To be included, the study must have reported clinical data on adult (A-CA) or pediatric (P-CA) cancer patients and SOT or HCT recipients with confirmed COVID-19. Our inclusion and exclusion criteria identified 64 SOT studies, 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 , 90 11 HCT studies,…”

Section: Methodsmentioning

confidence: 99%

COVID-19 in immunocompromised patients: A systematic review of cancer, hematopoietic cell and solid organ transplant patients

Belsky¹,

Tullius²,

Lamb³

et al. 2021

Journal of Infection

191

166

View full text Add to dashboard Cite

Background: The clinical impact of severe coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in immunocompromised patients has not been systematically evaluated. Methods: We reviewed current literature reporting on COVID-19 in cancer (CA), hematopoietic cell (HCT), and solid organ transplant (SOT) patients and compared their clinical data and outcomes to the general population. For adult CA, HCT and SOT patients, an extensive search strategy retrieved all articles published until July 20, 2020 by combining the terms coronavirus, coronavirus infection, COVID-19 , and SARS-CoV-2 in PubMed, Cochrane, and Web of Science, and following the Preferred Reporting Items for Systematic Reviews and Meta-analysis guidelines. For the pediatric CA cohort, a global COVID-19 registry was used. For the general population cohort, a large meta-analysis was used to compare pooled prevalence estimates, and two large meta-analyses were utilized to serve as pooled comparators for hospitalized COVID-19 patients. Findings: Compared to the general population, adult CA and SOT patients with COVID-19 had higher comorbidities, greater levels of inflammatory markers at diagnosis, and higher rates of intensive care and hospital mortality. Pediatric CA patients and HCT patients with COVID-19 tended to have clinical presentations and outcomes similar to the general population. Interpretation: To our knowledge, this is the first systematic review evaluating COVID-19 phenotype and outcomes in immunocompromised patients and comparing them to the general population, which shows that hospital outcomes appear to be worse in adult CA and SOT patients, potentially due to their higher co-morbidity burden.

show abstract

“…Lung Transplant Recipients (LTRs) are among the most vulnerable groups in the COVID-19 pandemic (mortality 14-39%). [1][2][3][4] An early report provided evidence of a poor antibody response after the first mRNA vaccine dose in solid organ transplant recipients. 5 However, the immunogenicity of the novel mRNA COVID-19 complete 2-dose vaccine in LTRs is unknown to date.…”

Section: Introductionmentioning

confidence: 99%

Immunogenicity of BNT162b2 mRNA COVID-19 vaccine and SARS-CoV-2 infection in lung transplant recipients

Havlín

Svorcova

Dvořáčková

et al. 2021

The Journal of Heart and Lung Transplantation

112

130

View full text Add to dashboard Cite

show abstract

COVID‐19 in lung transplant recipients

Cited by 43 publications

References 5 publications

Clinical characteristics, management practices, and outcomes among lung transplant patients with COVID-19

Clinical characteristics, management practices, and outcomes among lung transplant patients with COVID-19

COVID-19 in immunocompromised patients: A systematic review of cancer, hematopoietic cell and solid organ transplant patients

Immunogenicity of BNT162b2 mRNA COVID-19 vaccine and SARS-CoV-2 infection in lung transplant recipients

Contact Info

Product

Resources

About